首页> 美国卫生研究院文献>Cell Death Disease >MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET
【2h】

MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET

机译:MiR-34c通过靶向MET抑制鼻咽癌的肿瘤生长和转移

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our previous microarray analysis indicated that miR-34c was downregulated in nasopharyngeal carcinoma (NPC). However, little is known about the function and molecular mechanism of miR-34c in NPC. In this study, miR-34c was found to be significantly downregulated in NPC cell lines and clinical tissues. Ectopic expression of miR-34c suppressed NPC cell viability, colony formation, anchorage-independent growth, cell migration and invasion in vitro, and inhibited xenograft tumor growth and lung metastasis in vivo. MET proto-oncogene (MET) was identified as a direct target of miR-34c using luciferase reporter assays, quantitative RT-PCR, western blotting and immunofluorescent staining. Overexpression of miR-34c markedly reduced MET expression at both the mRNA and protein levels. Knockdown of MET suppressed NPC cell proliferation, migration and invasion, whereas the restoration of MET rescued the suppressive effects of miR-34c. The demethylation agent 5-aza-2′-deoxycytidine (DAC) restored the expression of miR-34c in NPC cell lines. The promoter region of miR-34c was hypermethylated in NPC cells. In conclusion, miR-34c suppresses tumor growth and metastasis in NPC by targeting MET. The newly identified miR-34c/MET pathway provides further insights into the development and progression of NPC, and may represent a novel therapeutic target for NPC treatment.
机译:我们以前的微阵列分析表明,miR-34c在鼻咽癌(NPC)中被下调。但是,关于miR-34c在NPC中的功能和分子机制的了解甚少。在这项研究中,发现miR-34c在NPC细胞系和临床组织中显着下调。 miR-34c的异位表达抑制了NPC细胞的活力,集落形成,锚定非依赖性生长,体外细胞迁移和侵袭,并在体内抑制了异种移植瘤的生长和肺转移。使用萤光素酶报告基因分析,定量RT-PCR,western印迹和免疫荧光染色,MET原癌基因(MET)被确定为miR-34c的直接靶标。 miR-34c的过度表达在mRNA和蛋白质水平上均显着降低MET表达。敲除MET可以抑制NPC细胞的增殖,迁移和侵袭,而MET的恢复可以挽救miR-34c的抑制作用。脱甲基剂5-氮杂-2'-脱氧胞苷(DAC)恢复了NPC细胞系中miR-34c的表达。 miR-34c的启动子区域在NPC细胞中被高度甲基化。总之,miR-34c通过靶向MET抑制NPC中的肿瘤生长和转移。新近鉴定的miR-34c / MET途径为NPC的发展和进程提供了进一步的见识,并且可能代表了NPC治疗的新治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号